SCHEMBL498694

SCHEMBL498694

O=C1OC2(c3ccc(O)cc3Oc3cc(OS(=O)(=O)O)ccc32)c2ccccc21

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 8/20 0.73
MAPT P10636 4/20 0.73
MEN1 O00255 4/20 0.73
KMT2A Q03164 4/20 0.73
TDP1 Q9NUW8 3/20 0.73
HTT P42858 2/20 0.73
HPGD P15428 2/20 0.73
RECQL P46063 2/20 0.73
BLM P54132 2/20 0.73
ACE2 Q9BYF1 2/20 0.73
CYP2C19 P33261 1/20 0.73
SMAD3 P84022 1/20 0.73
PRMT1 Q99873 1/20 0.73
LMNA P02545 3/20 0.60
ALDH1A1 P00352 3/20 0.60
USP2 O75604 2/20 0.60
CYP3A4 P08684 2/20 0.58
GPR55 Q9Y2T6 2/20 0.53
ALOX12 P18054 2/20 0.53
POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1030138 0.94 MAPT (0.67) FTOMAPTMEN1KMT2ATDP1
SCHEMBL6508177 0.91 FTO (0.70) FTOMAPTMEN1KMT2ATDP1
SCHEMBL6508174 0.90 FTO (0.72) FTOMAPTMEN1KMT2ATDP1
SCHEMBL21638745 0.90 FTO (0.72) FTOMAPTMEN1KMT2ATDP1
SCHEMBL19549132 0.89 FTO (0.57) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL5872682 0.88 FTO (0.89) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL28273623 0.88 FTO (0.89) FTOMAPTMEN1KMT2ATDP1
Fluorescein SCHEMBL9844354 0.88 FTO (0.89) FTOMAPTMEN1KMT2ATDP1
SCHEMBL19386225 0.88 FTO (0.69) FTOMAPTMEN1KMT2ATDP1
SCHEMBL4663321 0.87 FTO (0.82) FTOMAPTMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3661539-B1 OPTIMIZED PEPTIDES FOR TARGETING HUMAN NERVES AND THEIR USE IN IMAGE GUIDED SURGERY, DIAGNOSTICS AND THERAPEUTIC DELIVERY UNIV CALIFORNIA (US) 2024-10-09 EP claimed
US-20240207421-A1 NERVE TARGETING PEPTIDES AND METHODS OF USE ALUME BIOSCIENCES INC (US) 2024-06-27 US claimed
CN-118103706-A DHEAS assay, reagents for DHEAS assay, and methods of making and using the same 美国西门子医学诊断股份有限公司 2024-05-28 CN claimed
US-11802138-B2 Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostic and therapeutic delivery THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-10-31 US claimed
CN-116916971-A Methods and compositions for ureter visualization in surgical procedures 阿鲁莫生物科学公司 2023-10-20 CN claimed
US-20230257428-A1 METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES Blaze Bioscience, Inc. 2023-08-17 US claimed
CN-116063472-A anti-Spike S2 protein antibody and application thereof 江苏东抗生物医药科技有限公司 2023-05-05 CN claimed
WO-2022155385-A1 METHODS AND COMPOSITIONS FOR VISUALIZING A URETER IN A SURGICAL PROCEDURE ALUME BIOSCIENCES, INC. (US) 2022-07-21 WO claimed
WO-2022120177-A1 NERVE TARGETING PEPTIDES AND METHODS OF USE ALUME BIOSCIENCES, INC. (US) 2022-06-09 WO claimed
US-11299515-B2 Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-04-12 US claimed
US-8658037-B2 Method for determining physiological state of microbial community and wastewater treatment method SEIKO PMC CORPORATION (JP) 2014-02-25 US claimed
US-20110100903-A1 METHOD FOR DETERMINING PHYSIOLOGICAL STATE OF MICROBIAL COMMUNITY AND WASTEWATER TREATMENT METHOD SEIKO PMC CORPORATION (JP) 2011-05-05 US claimed
US-6696241-B2 MEASURING ESTERASE ACTIVITY THE REGENT OF THE UNIVERSITY OF CALIFORNIA 2004-02-24 US claimed
US-20010049091-A1 Use of fluorescent reagents in identification of cancerous cells and activated lymphocytes THOMPSON JAMES (US) 2001-12-06 US claimed
WO-2000003033-A9 USE OF FLUORESCENT REAGENTS IN IDENTIFICATION OF CANCEROUS CELLS AND ACTIVATED LYMPHOCYTES UNIV CALIFORNIA (US) 2000-10-05 WO claimed
WO-2000003033-A1 USE OF FLUORESCENT REAGENTS IN IDENTIFICATION OF CANCEROUS CELLS AND ACTIVATED LYMPHOCYTES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-01-20 WO claimed
EP-0267049-A2 Method of determining endothelial cell coverage of a prosthetic surface THOMAS JEFFERSON UNIVERSITY (US) 1988-05-11 EP claimed
JP-56084786-A None JP disclosed
EP-0267049-A2 Method of determining endothelial cell coverage of a prosthetic surface THOMAS JEFFERSON UNIVERSITY (US) 1988-05-11 EP disclosed
JP-S5684786-A REVERSIBLE TEMPERATURE-INDICATING MATERIAL DAINIPPON PRINTING CO LTD 1981-07-10 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257428-A1 METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES CHLSN, SLC47A1, CLSPN FTO 3230/4885MAPT 2934/4885MEN1 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.